Timing the Next Wave of Strategic M&A

Despite softening valuations among public biotechs and a major tightening of post-series B private funding rounds, the strategic M&A deal volume of large biopharmas still remains below historical averages, with highly targeted deals in new modalities getting most traction.  This session will explore when to expect deal flow to rise and how biotech companies should best position themselves to maximize value from being acquired in a friendly deal, if sought.